Movement Alert｜GRAIL, Inc. Intraday Rise 5.43% in Regular Trading, FDA review momentum and a higher UBS target supported shares

Market Focus10-28

On October 28, GRAIL, Inc. recorded an Intraday Rise of 5.43% in Regular Trading, trading at $158.2919 per share with turnover of $21.4773 million.

The move was supported by continued optimism around Galleri after the FDA advisory committee recommended the multi-cancer early detection test, alongside UBS raising its price target to $175 from $105 while maintaining a Buy rating.

Background developments show the advisory committee voted 10 to 0 on safety, 6 to 4 on efficacy, and 7 to 2 with one abstention on benefit-risk. Recent commentary indicated the review focus had shifted more toward product positioning and labeling rather than core safety concerns, reinforcing expectations for regulatory progress and commercialization potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment